Cuba Cancer Treatment

Skıp The Waıtıng Room!

Register Online Before You Arrive.

We have up to date schedules, contact information, & let you book appointments online.

Why choose Cuba as a destination for treatment?

Cuba has always stood out for presenting a health system of excellence, which includes both medical care personnel and hospital institutions. So much so, that it has been recognized by the World Health Organization (WHO) as a potential medical the height of developed countries.

Taking into account its multiple medical advances in the treatment of people with cancer aimed at improving their quality of life, this country has become a reference point for medical tourism, with the most advanced techniques and highly specialized personnel in this field. These advances are the result of Cuba’s scientific and technical development in combination with the National Biotechnology and Pharmaceutical Industry, providing exclusive medical programs.

Types of treatment provided

As a comprehensive program in the fight against cancer, several therapeutic vaccines have been developed as part of immunotherapy combined with the use of chemotherapy as the first line of treatment. Cımavax and Vaxıra, developed for non-small cell lung cancer in advanced stages , increase the patient’s life expectancy-in many cases exceeding 5 years, in addition to improving the respiratory capacity, physical and emotional state of the patients; CIMAher, a humanized monoclonal antibody, is offered as an alternative to people with advanced head and neck cancer, and is also used in patients with malignant esophageal tumors and non-small cell lung cancer.

Vaccines Used:

1-CIMAVAX-EGF®.

(Chemical conjugate of human Epidermal Growth Factor

recombinant coupled to the recombinant protein P64K).

Therapeutic indications:

CIMAVAX-EGF® is indicated in patients with non-small cell lung cancer, in advanced stages (IIIb / IV), after first-line chemotherapy and with high concentrations of Epidermal Growth Factor in serum.

Treatment phases:

Treatment consists of a 1st induction phase that begins with the administration of cyclophosphamide.Three days later, the administration of CIMAvax-EGF® begins, every 14 days for the first 4 doses.

The 2nd phase is maintenance and includes monthly re-immunizations that will be maintained until the patient’s general condition allows it.

CIMAVAX-EGF® is administered intramuscularly.

2-VAXIRA® (Racotumomab)

Therapeutic indications:

For the treatment of patients with non-small cell lung carcinoma (NSCLC), in advanced stages (III b or IV), with objective clinical response or stable disease after first-line oncospecific chemotherapy-radiotherapy treatment (change maintenance ).

Treatment phases:

Induction stage: The first five doses will be administered 14 days apart.

Maintenance stage: includes reimmunizations every 28 days until the patient presents unacceptable toxicity or deterioration of their general condition.

During the first 2 doses of VAXIRA®, the patient will remain under observation for one hour, in order to ensure the detection of immediate adverse reactions and timely treatment. The patient does not need to remain under observation for subsequent doses if no these reactions during the first two doses, unless considered by the doctor. There is no evidence that indicates the need to use prior medication. Symptomatic treatment is only suggested if necessary.

Each subdose is administered at a different anatomical site. Recommended sites for

immunization are: the deltoid region, the anterior aspect of the forearm, the anterior aspect of the thigh and the posterior aspect of the calf.

3-CIMAHER® (Nimotuzumab)

 Therapeutic indications:

– Treatment of head and neck tumors in advanced stages in combination with radiotherapy and/or chemotherapy.

– Treatment of adult patients with highly malignant glial tumors: glioblastoma multiforme and anaplastic astrocytoma, in combination with radiotherapy.

– Treatment of pediatric patients with newly diagnosed high-grade glial tumors, in combination with radiotherapy and radiochemotherapy.

– Treatment of pediatric patients with recurrent or refractory glial tumors with nimotuzumab.

– Treatment of patients with non-operable malignant esophageal tumors of epithelial origin in combination with radiochemotherapy.

– Treatment of patients with locally advanced adenocarcinoma or metastatic disease of the pancreas, in combination with chemotherapy.

– Maintenance treatment of patients with non-small cell lung cancer, in advanced stages and non-progressors, to the first line of chemotherapy.

– Treatment of patients with severe and moderate COVID-19 pneumonia.

 Treatment phases:

-1st Phase: Induction: once a week for 6 weeks, concomitant with radiotherapy and/or chemoradiotherapy, after evaluating the response to the

first line of chemotherapy (patients who have not progressed to their disease will be treated, including patients with stable disease, partial and complete responses to this previous therapy).

-2nd Phase: Maintenance: one dose every 15 days until the condition

patient’s general condition allows it.

As a supplementary method, several products have been developed that stand out for their effectiveness in both oncology patients and patients with other conditions. The following are thus counted:

 

VIDATOX® 30CH

Vidatox, manufactured and registered in Cuba, is an alternative medicine against Cancer that is produced from the venom of the scorpion Rhopalurus junceus, endemic to Cuba, which has proven antitumor, anti-inflammatory and analgesic values, considerably relieves clinical symptoms and prolongs survival. from the patients.

With an efficiency capable of improving the quality of life of those suffering from cancer, Vidatox is used as a complement to oncospecific therapies, mainly in the varieties of breast, liver, brain, prostate and lung carcinomas, without causing the secondary reactions produced by chemotherapies and radiotherapies.

It is a potentially non-toxic product taken orally. Its use does not exclude or limit other conventional measures of oncological treatment, on the contrary.

With the application of Vidatox® 30CH in patients with cancer in different locations and stages, the following has been achieved:

– Improve Life Quality

– Symptomatic improvement

– Pain relief

– Prolong survival

 

Trofın Vıtal

Trofin-Vital is an oral solution with restorative properties mineral and antianemic protein, which is indicated to prevent, reduce and eliminate iron and protein deficiency states, malnutrition, exhaustion, asthenia, decay in the elderly, pregnant women, children and iron deficiency anemia, also used in the treatment of anemia in patients with cancer, gastrointestinal diseases, in which no adverse reactions were reported.

It has an effectiveness between 85 and 90 percent in increasing hemoglobin, in addition its action has been demonstrated as a revitalizing, restoring and invigorating,

Studies carried out have shown that Trofin-Vital positively influences the nutritional status of these patients, maintaining the treatment for more than 4 months with a dose of two tablespoons per day.

Anamu

Anamu (Petiveria Alliacea) is a common herb in the Amazon and tropical areas of Central and South America, the Caribbean and Africa, used against arthritis, malaria, rheumatism, memory problems, as an analgesic and anti-inflammatory.

This is the first Cuban natural oral tablet to combat cellular immunodeficiency. In Cuba, a decoction of the entire plant is used in cases of cancer and diabetes, and as an antiviral and antitumor due to its proven antileukemic and cytotoxic effects against various types of cancer cells.

Need some advice from our experts?

Request a Call Back Today Now!

We will make a single attempt to contact you from a withheld number, usually within 24 hours of your request.